Laia Grau-López
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laia Grau-López has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Ramo-Tello
Hospital Germans Trias i Pujol, Badalona, Spain
14 shared publications - Eva María Martínez Cáceres
Division of Immunology, LCMN, Germans Trias i Pujol University Hospital and Research Institute, Badalona, Spain
12 shared publications - Francesc Enric Borràs
REMAR‐IVECAT Group, “Germans Trias i Pujol” Health Science Research Institute and Nephrology Department “Germans Trias i Pujol” University Hospital Badalona Spain
6 shared publications - Mar Naranjo-Gomez
IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France
6 shared publications Jordi Ciurans
Department of Neurosciences, Hospital Germans Trias i Pujol, C/ Canyet s/n, 08916, Badalona, Spain
5 shared publications- Juan Luis Becerra
Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
5 shared publications
Latest Publications
- 1 November 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 124, 108310
Clinical factors associated with work disability in epilepsy: A cross-sectional study at a tertiary referral hospital
- 1 November 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 124, 108310
Clinical factors associated with work disability in epilepsy: A cross-sectional study at a tertiary referral hospital
- 1 April 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 117, 107766
Psychogenic nonepileptic seizures: The effect of accurate diagnosis on cognition
- 1 April 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 117, 107766
Psychogenic nonepileptic seizures: The effect of accurate diagnosis on cognition
Blood biomarkers predictive of epilepsy after an acute stroke event
Objective: Blood biomarkers have not been widely investigated in poststroke epilepsy. In this study, we aimed to describe clinical factors and biomarkers present during acute stroke and analyze their association with the development of epilepsy at long term.Methods: A panel of 14 blood biomarkers was evaluated in patients with ischemic and hemorrhagic stroke. Biomarkers were normalized and standardized using Z‐scores. Stroke and epilepsy‐related variables were also assessed: stroke severity, determined by National Institutes of Health Stroke Scale (NIHSS) score, stroke type and cause, time from stroke to onset of late seizures, and type of seizure. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with epilepsy.Results: From a cohort of 1115 patients, 895 patients were included. Mean ± standard deviation (SD) age was 72.0 ± 13.1 years, and 57.8% of patients were men. Fifty‐one patients (5.7%) developed late seizures, with a median time to onset of 232 days (interquartile range [IQR] 86‐491). NIHSS score ≥8 (P < .001, hazard ratio [HR] 4.013, 95% confidence interval [CI] 2.123‐7.586) and a history of early onset seizures (P < .001, HR 4.038, 95% CI 1.802‐9.045) were factors independently associated with a risk of developing epilepsy. Independent blood biomarkers predictive of epilepsy were high endostatin levels >1.203 (P = .046, HR 4.300, 95% CI 1.028‐17.996) and low levels of heat shock 70 kDa protein‐8 (Hsc70) P = .006, HR 3.795, 95% CI 1.476‐9.760) and S100B P = .001, HR 2.955, 95% CI 1.534‐5.491). The risk of epilepsy when these biomarkers were combined increased to 17%. The area under the receiver‐operating characteristic (ROC) curve of the predictive model was stronger when clinical variables were combined with blood biomarkers (74.3%, 95% CI 65.2%‐83.3%) than when they were used alone (68.9%, 95% CI 60.3%‐77.6%).Significance: Downregulated S100B and Hsc70 and upregulated endostatin may assist in prediction of poststroke epilepsy and may provide additional information to clinical risk factors. In addition, these data are hypothesis‐generating for the epileptogenic process.
Blood biomarkers predictive of epilepsy after an acute stroke event
Objective: Blood biomarkers have not been widely investigated in poststroke epilepsy. In this study, we aimed to describe clinical factors and biomarkers present during acute stroke and analyze their association with the development of epilepsy at long term.Methods: A panel of 14 blood biomarkers was evaluated in patients with ischemic and hemorrhagic stroke. Biomarkers were normalized and standardized using Z‐scores. Stroke and epilepsy‐related variables were also assessed: stroke severity, determined by National Institutes of Health Stroke Scale (NIHSS) score, stroke type and cause, time from stroke to onset of late seizures, and type of seizure. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with epilepsy.Results: From a cohort of 1115 patients, 895 patients were included. Mean ± standard deviation (SD) age was 72.0 ± 13.1 years, and 57.8% of patients were men. Fifty‐one patients (5.7%) developed late seizures, with a median time to onset of 232 days (interquartile range [IQR] 86‐491). NIHSS score ≥8 (P < .001, hazard ratio [HR] 4.013, 95% confidence interval [CI] 2.123‐7.586) and a history of early onset seizures (P < .001, HR 4.038, 95% CI 1.802‐9.045) were factors independently associated with a risk of developing epilepsy. Independent blood biomarkers predictive of epilepsy were high endostatin levels >1.203 (P = .046, HR 4.300, 95% CI 1.028‐17.996) and low levels of heat shock 70 kDa protein‐8 (Hsc70) P = .006, HR 3.795, 95% CI 1.476‐9.760) and S100B P = .001, HR 2.955, 95% CI 1.534‐5.491). The risk of epilepsy when these biomarkers were combined increased to 17%. The area under the receiver‐operating characteristic (ROC) curve of the predictive model was stronger when clinical variables were combined with blood biomarkers (74.3%, 95% CI 65.2%‐83.3%) than when they were used alone (68.9%, 95% CI 60.3%‐77.6%).Significance: Downregulated S100B and Hsc70 and upregulated endostatin may assist in prediction of poststroke epilepsy and may provide additional information to clinical risk factors. In addition, these data are hypothesis‐generating for the epileptogenic process.
- Open Access
- 1 March 2018
- Published by Elsevier in Neurología
- Vol. 33 (2) , 135-137
Multineuritis craneal como comienzo de lupus eritematoso sistémico: un reto diagnóstico
- 1 March 2018
- Published by Elsevier in Neurología
- Vol. 33 (2) , 135-137
Open AccessMultineuritis craneal como comienzo de lupus eritematoso sistémico: un reto diagnóstico
- 1 December 2017
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 40 (10) , 709-717
Manifestaciones neurológicas del alcoholismo
- 1 December 2017
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 40 (10) , 709-717
Manifestaciones neurológicas del alcoholismo
- 29 November 2017
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 53 (8) , 1267-1274
Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study
Introduction: Pharmacological treatment of insomnia in patients with addictions has been hardly investigated and there are few researches about it in an inpatient detoxification. The aim of this study was to describe the outcomes of the pharmacological treatment of insomnia in SUD patients admitted to a detoxification unit in Spain, with a focus on the primary substance of abuse and co-occurring mental disorders. Methods: A quasi-experimental study was conducted in 481 addicted in patients, who were admitted for substances detoxification in Vall d´Hebron University Hospital, Barcelona, Spain, from 2010 to 2015. The patients underwent systematic evaluation of axes I and II psychiatric disorders (SCID-I, SCID-II, and CAADID). Insomnia was evaluated using a night time sleep log. Substance-dependent patients, who had insomnia during hospital detoxification, received a psychotropic medication with hypnotic effect, keeping the regular clinical practice without randomization. Results: At discharge, insomnia was considered to have been alleviated in 63.8% (n = 204) of patients while 36.2% (n = 116) of patients remained with insomnia disturbances. Comparing hypnotic treatments it was observed that mirtazapine and clotiapine were the treatment that corrected the insomnia more frequently. Discussion: Since insomnia is not corrected in all patients, it should be further investigated in medications with hypnotic purpose. Based on the results of this work, randomized clinical trials might be proposed.
- 29 November 2017
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 53 (8) , 1267-1274
Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study
Introduction: Pharmacological treatment of insomnia in patients with addictions has been hardly investigated and there are few researches about it in an inpatient detoxification. The aim of this study was to describe the outcomes of the pharmacological treatment of insomnia in SUD patients admitted to a detoxification unit in Spain, with a focus on the primary substance of abuse and co-occurring mental disorders. Methods: A quasi-experimental study was conducted in 481 addicted in patients, who were admitted for substances detoxification in Vall d´Hebron University Hospital, Barcelona, Spain, from 2010 to 2015. The patients underwent systematic evaluation of axes I and II psychiatric disorders (SCID-I, SCID-II, and CAADID). Insomnia was evaluated using a night time sleep log. Substance-dependent patients, who had insomnia during hospital detoxification, received a psychotropic medication with hypnotic effect, keeping the regular clinical practice without randomization. Results: At discharge, insomnia was considered to have been alleviated in 63.8% (n = 204) of patients while 36.2% (n = 116) of patients remained with insomnia disturbances. Comparing hypnotic treatments it was observed that mirtazapine and clotiapine were the treatment that corrected the insomnia more frequently. Discussion: Since insomnia is not corrected in all patients, it should be further investigated in medications with hypnotic purpose. Based on the results of this work, randomized clinical trials might be proposed.
- 7 September 2017
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 43 (7) , 636-640
Incidental neuronal intermediate filament inclusion pathology: unexpected biopsy findings in a 37‐year‐old woman with epilepsy
- 7 September 2017
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 43 (7) , 636-640
Incidental neuronal intermediate filament inclusion pathology: unexpected biopsy findings in a 37‐year‐old woman with epilepsy
- 1 September 2017
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 34 (5) , 434-437
Diagnostic Yield of Routine Electroencephalography With Concurrent Video Recording in Detecting Interictal Epileptiform Discharges in Relation to Reasons for Request: A Prospective Study of 1,080 Video-Electroencephalograms
The aim of this study was to prospectively analyze the sensitivity and specificity of routine electroencephalography with concurrent video recording (vEEG) in relation to the reasons for requesting the test and to investigate when routine vEEG should be requested. We prospectively analyzed 1,080 consecutive vEEGs performed between April 2015 and April 2016. The requests for vEEG were classified as requests with a low suspicion of epilepsy (syncope, confusion or delirium, suspicion of psychogenic nonepileptic seizures, and paroxysmal focal neurological deficit) or requests with a high suspicion of epilepsy (first clinical seizure, suspected status epilepticus, follow-up study of a patient with epilepsy, and acute symptomatic seizures). Predominant vEEG findings (ictal and interictal epileptiform activities, diffuse, or focal slowing and triphasic waves) were analyzed, and sensitivity and specificity [ZERO WIDTH SPACE][ZERO WIDTH SPACE]values calculated. The most common indication for vEEG was a follow-up study of patients with epilepsy (38%), followed by first clinical seizure (19.3%) and suspected status epilepticus (11%). The respective specificity and sensitivity values were 93% and 58% for 235 vEEGs performed in children/adolescents (≤18 years), 95% and 40% for 533 vEEGs performed in adults (>18 ≤ 65 years), and 93% and 39% for 312 vEEGs performed in older adults (>65 years). Twenty-four patients with false-positive paroxysms had a clinical diagnosis of confusional state or paroxysmal focal neurological deficit. Neurologists and neuropediatricians with experience in managing epilepsy had higher specificity values than general neurologists or physicians (P = 0.012). In our series, vEEG abnormalities were mainly observed in patients with clinical findings highly suggestive of epilepsy. In confusional states, and paroxysmal focal neurological deficit vEEG could be indicated.
- 1 September 2017
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 34 (5) , 434-437
Diagnostic Yield of Routine Electroencephalography With Concurrent Video Recording in Detecting Interictal Epileptiform Discharges in Relation to Reasons for Request: A Prospective Study of 1,080 Video-Electroencephalograms
The aim of this study was to prospectively analyze the sensitivity and specificity of routine electroencephalography with concurrent video recording (vEEG) in relation to the reasons for requesting the test and to investigate when routine vEEG should be requested. We prospectively analyzed 1,080 consecutive vEEGs performed between April 2015 and April 2016. The requests for vEEG were classified as requests with a low suspicion of epilepsy (syncope, confusion or delirium, suspicion of psychogenic nonepileptic seizures, and paroxysmal focal neurological deficit) or requests with a high suspicion of epilepsy (first clinical seizure, suspected status epilepticus, follow-up study of a patient with epilepsy, and acute symptomatic seizures). Predominant vEEG findings (ictal and interictal epileptiform activities, diffuse, or focal slowing and triphasic waves) were analyzed, and sensitivity and specificity [ZERO WIDTH SPACE][ZERO WIDTH SPACE]values calculated. The most common indication for vEEG was a follow-up study of patients with epilepsy (38%), followed by first clinical seizure (19.3%) and suspected status epilepticus (11%). The respective specificity and sensitivity values were 93% and 58% for 235 vEEGs performed in children/adolescents (≤18 years), 95% and 40% for 533 vEEGs performed in adults (>18 ≤ 65 years), and 93% and 39% for 312 vEEGs performed in older adults (>65 years). Twenty-four patients with false-positive paroxysms had a clinical diagnosis of confusional state or paroxysmal focal neurological deficit. Neurologists and neuropediatricians with experience in managing epilepsy had higher specificity values than general neurologists or physicians (P = 0.012). In our series, vEEG abnormalities were mainly observed in patients with clinical findings highly suggestive of epilepsy. In confusional states, and paroxysmal focal neurological deficit vEEG could be indicated.